Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 100

Testing antiarrhythmic drugs for atrial fibrillation based on genetics

Official title: A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs

Run by University of Illinois Chicago · NCT02347111 · Data updated 2026-11-12

This study is testing if two different heart medications can help people with frequent atrial fibrillation based on their genetic makeup.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 100 Years
SexAll
Enrollment162 (estimated)
SponsorUniversity of Illinois Chicago
Academic / other
Locations4 sites (Chicago, Illinois and 3 other locations)
StatusRecruiting
StartedDecember 31, 2020
Main results expectedJune 30, 2026
Study endsJune 30, 2026
Registry record updatedAugust 24, 2025
Trial IDNCT02347111 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with a history of symptomatic paroxysmal or persistent atrial fibrillation.

Probably not a fit

Patients with permanent atrial fibrillation or those who have previously undergone AF ablation may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) to evaluate the effectiveness of two different classes of antiarrhythmic drugs (AADs), Flecainide and Sotalol. Participants will be assessed in a cross-over design to gather preliminary data on how a common genetic risk allele may influence their response to these medications. The study seeks to address the variability in treatment response and improve the understanding of genetic factors contributing to AF. Ultimately, this research could pave the way for more personalized treatment strategies for patients with AF.

Why it matters

Potential benefit: If successful, this study could lead to more effective and personalized treatment options for patients with atrial fibrillation.

How similar studies have gone: While the approach of using genetic factors to guide treatment is gaining traction, this specific study is among the first to directly test the impact of genetic risk alleles on the response to antiarrhythmic drugs in AF.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* ≥ 18 years of age
* History of typical or early-onset symptomatic (≥2 episodes/month) paroxysmal/persistent AF
* ECG that was recorded within 1 month of randomization showing AF
* Eligible for both Flecainide(Class I) and Sotalol (Class III) AAD
* Able to give informed consent

Exclusion Criteria:

* Permanent AF or isolated atrial flutter
* Cardiac or thoracic surgery within the previous 6 months
* Previous use of amiodarone other than short-term use (e.g. for an acute arrhythmia in hospital)
* Medical condition that is likely to be fatal in less than one year
* A history of prior AF ablation
* Have already been tried on 2 or more AADs in the past for AF
* Creatinine clearance \<40 ml/min
* Left ventricular ejection fraction \< 50%
* Contra-indication to a Class I AAD e.g., structural heart disease, or history of MI
* Contra-indication to a Class III AAD, e.g., congenital or acquired long QT syndrome with QTc\>480 ms in females and \>460 ms in males at baseline
* A reversible cause of AF (e.g., hyperthyroidism)
* Females who are pregnant or nursing
* History of severe AV node dysfunction unless an electronic pacemaker is present
* First- or second-degree relative has already participated in the study
* Unable to adhere to study procedures that are strictly for research purposes

Where it's running

  • University of Illinois at Chicago
    Chicago, Illinois, United States
    Recruiting
  • Jesse Brown VA Medical Center
    Chicago, Illinois, United States
    Not yet recruiting
  • Rush University Medical Center
    Chicago, Illinois, United States
    Not yet recruiting
  • Advocate Christ Medical Center
    Oak Lawn, Illinois, United States
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.